Novartis faces whistleblower claims of bribery in Turkey

Novartis ($NVS) faces bribery allegations in yet another country. A whistleblower has accused the Swiss drugmaker of paying bribes in Turkey to increase prescriptions of its drugs, Reuters reports. More from FiercePharma

Suggested Articles

Doctor putting stethescope to patient's chest
Pharma

ACC: Esperion's Nexletol busts cholesterol despite other therapy

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

by Kyle Blankenship
Bluebird Bio CEO snares $24 million pay package as gene therapy advance
Marketing

Coronavirus disrupts Bluebird's Zynteglo plans

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

by Angus Liu
Marketing

New dashboard tracks top COVID-19 news in life science industry

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.

by Beth Snyder Bulik